Get the Stockscreener App
6.88
1.29%
-0.09
After Hours:
6.85
-0.03
-0.44%
Novavax Inc stock is traded at $6.88, with a volume of 3.79M.
It is down -1.29% in the last 24 hours and down -0.86% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$6.97
Open:
$7.02
24h Volume:
3.79M
Relative Volume:
0.45
Market Cap:
$1.11B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-3.0044
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
-2.27%
1M Performance:
-0.86%
6M Performance:
-19.53%
1Y Performance:
-54.50%
1-Day Range:
$6.71
$7.06
1-Week Range:
$6.71
$7.20
52-Week Range:
$5.01
$17.81
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.88 | 1.14B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.20 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.96 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.12 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.96 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.70 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax (NVAX) Rises Higher Than Market: Key Facts - Yahoo Finance
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax's Dual Vaccine Strategy: Navigating Near-Term Hurdles to Long-Term Growth Potential - AInvest
Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth (NASDAQ:NVAX) - Seeking Alpha
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet - Yahoo Finance
Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. (NVAX) Investors with Substantial Losses to Contact the Firm - ACCESS Newswire
Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating - MSN
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks - Benzinga
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval - Benzinga
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now? - Yahoo Finance
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Novavax jumps 15% on COVID shot nod, among 14 FDA approvals in May - BioWorld MedTech
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus
Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigroup | NVAX Stock News - GuruFocus
Citi initiates Novavax stock with sell rating on strategy shift concerns - Investing.com UK
Novavax (NVAX) Receives Initial 'Sell' Rating from Citi | NVAX Stock News - GuruFocus
Novavax: New Vaccine, Same Old StoryStill A Sell (NASDAQ:NVAX) - Seeking Alpha
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
Ruxandra Draghia-Akli, MD, PhD - Novavax
Novavax: positive results for Covid/flu vaccine - MarketScreener
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response - Yahoo Finance
Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals - The Pharma Letter
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Pipelinereview
RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report - Benzinga
Novavax at Goldman Sachs Healthcare Conference: Strategic Shift to R&D Focus - Investing.com Nigeria
RFK Jr. picks eight new members to CDC vaccine advisory panel - Seeking Alpha
Novavax's COVID-19-Influenza Combination and Stand-alone Influen - GuruFocus
Novavax (NVAX) Phase 3 Trial Shows Promising Results in Vaccine Study | NVAX Stock News - GuruFocus
Novavax reports positive results for COVID-19 and flu vaccine candidates By Investing.com - Investing.com South Africa
Transcript : Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com
Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates - Yahoo Finance
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Benzinga
Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Novavax's COVID-flu combo vaccine shows strong immune response in trial - Reuters
Novavax (NVAX) Reports Promising Results for COVID-19-Flu Vaccine Combo - GuruFocus
Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall By Investing.com - Investing.com Canada
Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study - marketscreener.com
Novavax stock gains on data for COVID-flu shot (NVAX:NASDAQ) - Seeking Alpha
Novavax reports positive results for COVID-19 and flu vaccine candidates - Investing.com Canada
Novavax (NVAX) Reports Positive Results for COVID-Influenza Comb - GuruFocus
Novavax Reports Promising Phase 3 Vaccine Trial Results - TipRanks
Novavax (NVAX) Reports Positive Results for COVID-Influenza Combo Vaccine Trial | NVAX Stock News - GuruFocus
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study - marketscreener.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):